ABIVAX Société Anonyme (AAVXF)
USD 11.05
(0.0%)
USD 11.05
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 327.06 Million EUR | 345.88% |
| 2022 | 73.35 Million EUR | -33.54% |
| 2021 | 110.36 Million EUR | 54.79% |
| 2020 | 71.29 Million EUR | 37.83% |
| 2019 | 51.72 Million EUR | -4.29% |
| 2018 | 54.04 Million EUR | 0.43% |
| 2017 | 53.81 Million EUR | -11.19% |
| 2016 | 60.59 Million EUR | -20.55% |
| 2015 | 76.26 Million EUR | 100.88% |
| 2014 | 37.96 Million EUR | -1.29% |
| 2013 | 38.46 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 284.49 Million EUR | 0.0% |
| 2024 Q1 | 284.49 Million EUR | -13.02% |
| 2023 FY | 327.06 Million EUR | 345.88% |
| 2023 Q3 | 327.06 Million EUR | 91.17% |
| 2023 Q1 | 171.08 Million EUR | 133.23% |
| 2023 Q4 | 327.06 Million EUR | 0.0% |
| 2023 Q2 | 171.08 Million EUR | 0.0% |
| 2022 Q1 | 71.64 Million EUR | -35.09% |
| 2022 Q4 | 73.35 Million EUR | -2.9% |
| 2022 Q3 | 75.54 Million EUR | 5.45% |
| 2022 Q2 | 71.64 Million EUR | 0.0% |
| 2022 FY | 73.35 Million EUR | -33.54% |
| 2021 Q2 | 55.09 Million EUR | 0.0% |
| 2021 Q3 | 109.23 Million EUR | 98.26% |
| 2021 Q4 | 110.36 Million EUR | 1.04% |
| 2021 FY | 110.36 Million EUR | 54.79% |
| 2021 Q1 | 55.09 Million EUR | -22.73% |
| 2020 Q1 | 49.81 Million EUR | -3.71% |
| 2020 Q2 | 49.81 Million EUR | 0.0% |
| 2020 Q3 | 71.29 Million EUR | 43.14% |
| 2020 Q4 | 71.29 Million EUR | 0.0% |
| 2020 FY | 71.29 Million EUR | 37.83% |
| 2019 Q4 | 51.72 Million EUR | 0.0% |
| 2019 Q1 | 54.59 Million EUR | 1.02% |
| 2019 Q3 | 51.72 Million EUR | -5.26% |
| 2019 FY | 51.72 Million EUR | -4.29% |
| 2019 Q2 | 54.59 Million EUR | 0.0% |
| 2018 Q3 | 54.04 Million EUR | 17.38% |
| 2018 FY | 54.04 Million EUR | 0.43% |
| 2018 Q2 | 46.04 Million EUR | 0.0% |
| 2018 Q1 | 46.04 Million EUR | -14.44% |
| 2018 Q4 | 54.04 Million EUR | 0.0% |
| 2017 Q4 | 53.81 Million EUR | 0.0% |
| 2017 Q3 | 53.81 Million EUR | -2.49% |
| 2017 Q2 | 55.18 Million EUR | 0.0% |
| 2017 Q1 | 55.18 Million EUR | -8.92% |
| 2017 FY | 53.81 Million EUR | -11.19% |
| 2016 Q2 | 66.66 Million EUR | 0.0% |
| 2016 Q4 | 60.59 Million EUR | 0.0% |
| 2016 Q3 | 60.59 Million EUR | -9.11% |
| 2016 Q1 | 66.66 Million EUR | -12.59% |
| 2016 FY | 60.59 Million EUR | -20.55% |
| 2015 FY | 76.26 Million EUR | 100.88% |
| 2015 Q3 | 76.26 Million EUR | -14.65% |
| 2015 Q4 | 76.26 Million EUR | 0.0% |
| 2015 Q1 | 89.35 Million EUR | 135.36% |
| 2015 Q2 | 89.35 Million EUR | 0.0% |
| 2014 Q4 | 37.96 Million EUR | 0.0% |
| 2014 Q3 | 37.96 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 FY | 37.96 Million EUR | -1.29% |
| 2013 FY | 38.46 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -741.923% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -4430.094% |
| SQZ Biotechnologies Company | 107.18 Million USD | -205.132% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -2998.939% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -151.179% |
| Mesoblast Limited | 667.9 Million USD | 51.031% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -451861.584% |
| Genus plc | 1.02 Billion USD | 68.212% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -23977.835% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -65438.365% |
| Marizyme, Inc. | 22.01 Million USD | -1385.627% |
| ContraFect Corporation | 20.67 Million USD | -1481.614% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -52062.998% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -83683.424% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -85478.672% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -22739.015% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -7788.574% |
| MultiCell Technologies, Inc. | 126.22 USD | -259120483.109% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -34705.345% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -154.503% |
| EV Biologics, Inc. | 431.71 Thousand USD | -75658.952% |
| Q BioMed Inc. | 3.51 Million USD | -9203.383% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -829.708% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -42340.089% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -125078.259% |
| Biomind Labs Inc. | 73.81 Thousand USD | -442959.375% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 29.338% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -989.664% |
| Skye Bioscience, Inc. | 11.94 Million USD | -2639.118% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -9772.044% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -11809.035% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -16602.269% |
| IMV Inc. | 31.33 Million USD | -943.8% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -47473.623% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -12463.864% |
| GB Sciences, Inc. | 103.44 Thousand USD | -316079.115% |
| Alpha Cognition Inc. | 2.45 Million USD | -13237.656% |
| HST Global, Inc. | 1526.00 USD | -21432534.338% |
| CSL Limited | 38.02 Billion USD | 99.14% |
| Halberd Corporation | 10.13 Thousand USD | -3228228.892% |
| Enzolytics Inc. | 361.7 Million USD | 9.578% |
| Resverlogix Corp. | 8.11 Million USD | -3930.339% |
| Affymax, Inc. | 7.44 Million USD | -4294.223% |
| SYBLEU INC | 330.46 Thousand USD | -98869.34% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -17316.555% |
| argenx SE | 4.54 Billion USD | 92.8% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -1070.419% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -585.636% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1435578.855% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -3554.669% |
| AVAX Technologies, Inc. | 7.37 Million USD | -4333.442% |
| Zenith Capital Corp. | 7410.00 USD | -4413692.173% |
| Genscript Biotech Corporation | 3.38 Billion USD | 90.342% |
| Ember Therapeutics, Inc. | 184.00 USD | -177750986.957% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -101533.282% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -125036.591% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 26.718% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -22474.013% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -10711.66% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -520.599% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -35145.231% |
| BioStem Technologies, Inc. | 14.56 Million USD | -2146.26% |
| ONE Bio Corp. | 70.08 Million USD | -366.661% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -572748.285% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -14158428.139% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -33004.547% |
| Agentix Corp. | 261.39 Thousand USD | -125023.187% |
| LadRx Corporation | 2.3 Million USD | -14071.522% |
| Cell Source, Inc. | 195.17 Thousand USD | -167477.15% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -67958.94% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -92390.463% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -92390.463% |
| NovAccess Global Inc. | 62.24 Thousand USD | -525317.684% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -51030.92% |
| Itoco Inc. | 1.4 Million USD | -23260.37% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -341811.204% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -308449.057% |
| Kadimastem Ltd | 2.3 Million USD | -14094.906% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -428249.53% |
| CytoDyn Inc. | 11.13 Million USD | -2836.979% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -228659.477% |
| Mobile Lads Corp. | 52.00 USD | -628965284.615% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1829105.817% |
| Qrons Inc. | 420.00 USD | -77871804.762% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -84747.369% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -59137.485% |
| Rebus Holdings, Inc. | 5000.00 USD | -6541140.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -79783.836% |
| International Stem Cell Corporation | 5.39 Million USD | -5967.941% |
| Bioxytran, Inc. | 137.63 Thousand USD | -237524.784% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -2080.147% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -1872.749% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -413902.532% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -37724.76% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -4250.964% |
| Neutra Corp. | 2851.00 USD | -11471734.444% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -909.264% |
| PureTech Health plc | 693.97 Million USD | 52.871% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -3952.266% |
| IXICO plc | 15.84 Million USD | -1964.277% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -3849.07% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -216.54% |
| CSL Limited | 38.02 Billion USD | 99.14% |
| Cellectis S.A. | 333.99 Million USD | 2.076% |